Approval · Notice of Compliance 9070 · 2007
COZAAR: Notice of Compliance 9070
Issued October 3, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9070
- Date
- October 3, 2007
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: antihypertensive effects of cozaar have been demonstrated in hypertensive pediatric patients aged 6 to 16 years. use of cozaar in these age groups is supported by evidence from adequate and well-controlled studies of cozaar in pediatric patients, and other revisions to the product monograph
- Therapeutic class
- Angiotensin ii receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COZAAR | Not yet assigned | — |
Medicinal ingredients
- LOSARTAN POTASSIUM 25 MG per TAB
- LOSARTAN POTASSIUM 50 MG per TAB
- LOSARTAN POTASSIUM 100 MG per TAB